Steven A. Shallcross - 15 Dec 2022 Form 4 Insider Report for Theriva Biologics, Inc. (TOVX)

Role
CEO and CFO, Director
Signature
/s/ Steven A. Shallcross
Issuer symbol
TOVX
Transactions as of
15 Dec 2022
Net transactions value
$0
Form type
4
Filing time
16 Dec 2022, 17:16:46 UTC
Previous filing
27 Dec 2021
Next filing
03 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TOVX Stock Options (right to buy) Award $0 +475,000 $0.000000 475,000 15 Dec 2022 Common Stock 475,000 $0.5800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options vest pro rata on a monthly basis over 36 months.